결절맥락막혈관병증에서 유리체강내 베바시주맙 주입술의 단기 효과

Short-term Efficacy of Intravitreal Bavacizumab for Polypoidal Choroidal Vasculopathy

Purpose: To evaluate the short-term effect of intravitreal bevacizumab (Avastin<sup>&#9415;) in polypoidal choroidal vasculopathy. Methods: Intravitreal Avastin<sup>&#9415; was injected into 13 eyes of 13 patients with PCV in this retrospective, interventional case study. The follow-up period lasted over 3 months after therapy. Changes in best-corrected visual acuity (BCVA), foveal height determined by optical coherence tomography, and abnormal vasculature in indocyanine green angiography (ICGA) were evaluated. Results: The mean LogMAR BCVA was 0.82 at baseline, 0.78 at 1 month after treatment, and 0.73 at 3 months after treatment. Visual acuity was stabilized or improved in 13 eyes (100%). The mean foveal height was 288 μm at baseline, 231 μm (p<0.05) at 1 month after treatment, and 196 μm at 3 months after treatment. The polypoidal lesions in ICGA decreased in 4 eyes (31%), although branching vasculature in ICGA was unchanged in 13 eyes (100%). Conclusions: Intravitreal injection of Avastin<sup>&#9415; may stabilize visual acuity and reduce macular edema due to decreased retinal pigment epithelial detachment and leaking. However, intravitreal injection had a minimal effect in occlusion of the symptomatic polypoidal lesions and no effect in occlusion of the branching vascular network.